Aditxt Inc

aditxt.com

What Do They Do?

Develops immune-modulating therapies and molecular tests for cancer detection, and provides immune-profile testing services for individuals and healthcare providers.

How Do They Make Money?

Aditxt charges for immune-testing services and earns the fee when it delivers a completed test report. Physicians and other entities are billed at negotiated rates, patients at established or physician-negotiated fees, and insurers reimburse by service.

FY2025 revenue

Who Are Their Customers?

AditxtScore testing is intended for individuals and their healthcare providers. Physicians and other entities are billed for services, patients may pay directly, and insurers reimburse for tests.

Do Revenues Turn Into Profits?

No. It lost $43.1M in FY2025.

Operating income, FY2025

−612542% of revenue

▼ −30% (Loss) vs FY2024 (−$27.9M, −20796%)

Net income, FY2025

−1349028% of revenue

▲ +7% (Loss) vs FY2024 (−$40.4M, −30118%)

Free cash flow, FY2025

−804448% of revenue

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q1 FY2026, the three months to Mar 31, 2026

Revenue: ▲ +1094%; vs $1K in Q1 FY2025
Net income: ▲ +179% (Loss); vs −$5.7M in Q1 FY2025

Sep 17, 2026 Nasdaq moved to delist Aditxt's common stock Trading had been suspended since June 25; Nasdaq said delisting would take effect ten days after it files Form 25.
Aug 19, 2026 MDNA Holdings acquired Pearsanta The buyer acquired Pearsanta's shares; Pearsanta agreed to royalty and milestone payments to Aditxt under specified conditions.
Jun 10, 2026 Signed an agreement to take Ignite public through a business combination The deal values Ignite at approximately $150 million and would put it under a newly formed public holding company, subject to closing conditions.
Jun 5, 2026 Board chair Brian Brady resigned

Shrinking. Revenue fell 97% in 4 years, from $105K in FY2021 to $3.2K in FY2025, about 58% a year.

Cancer-testing portfolio The older report listed immune-modulation and immune-monitoring programs; the latest adds Pearsanta's mitochondrial-DNA work on cancer biomarkers and test candidates.

Narrower AditxtScore license The older report described AditxtScore as immune-monitoring technology for a comprehensive immune profile; the latest says its exclusive sublicense ended and a non-exclusive license covers antibody testing.

Comments